IBIO

Companies
Nyse American
iBio, Inc.
Health Care
Price Chart
Overview

About IBIO

iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.

Market Cap
$20.9M
Volume
448.6K
Avg. Volume
681.5K
P/E Ratio
-1.2743902
Dividend Yield
0.00%
Employees
70.0

Company Information

Exchange
Nyse American
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.65
Low Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for IBIO.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, IBIO shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$20.9M
Volume448.6K
P/E Ratio-1.27
Dividend Yield0.00%
Important Dates
Next Dividend
June 11, 2018
Next Earnings
February 11, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how IBIO fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025